 TEL AVIV, Israel and BETHESDA, Md., June 28, 2021 PRNewswire -- Cannabics Pharmaceuticals Inc. OTCQB: CNBX, a global leader in the development of cancer related cannabinoid-based medicine, released today the interim results of its second in-vivo POC study evaluating the efficacy of companys proprietary drug candidate RCC-33 for the treatment of colorectal cancer on mice. 